Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2026/08/31 16:46 EDT
After Hours
Last
 799.0512
-0.0288 (0.00%)
Bid
799
Ask
814.08
High 801 
Low 798.9362 
Volume 83.21K 
Regular Hours (Closed)
Last
 799.08
+4.89 (+0.62%)
Day High 
802.78 
Prev. Close
794.19 
1-M High
847 
Volume 
754.30K 
Bid
799
Ask
814.08
Day Low
779.08 
Open
782.44 
1-M Low
691 
Market Cap 
81.77B 
Currency 美元 
P/E 19.65 
%Yield 0.46 
10-SMA 819.64 
20-SMA 802.69 
50-SMA 716.62 
52-W High 847 
52-W Low 541 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
40.41/54.16
Enterprise Value
84.47B
Balance Sheet
Book Value Per Share
308.01
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
14.34B
Operating Revenue Per Share
127.21
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3631 -0.0248 -6.39%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.2451 +0.0191 +8.45%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 34.45 -0.19 -0.55%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.69 -0.06 -3.43%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.4 -0.94 -0.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.